Abstract: RAGE is a central driver of tumorigenesis by sustaining an inflammatory tumor microenvironment. This study links the soluble forms of RAGE (sRAGE and esRAGE) with clinical outcome of melanoma patients. Moreover, tissue expression of RAGE was analyzed using immunohistochemistry on two independent tissue microarrays (TMA) containing 35 or 257 primary melanomas, and 41 or 22 benign nevi, respectively. Serum concentrations of sRAGE and esRAGE were measured in 229 stage III-IV patients using ELISA and plasma concentrations of sRAGE were analyzed in an independent second cohort with 173 samples of stage I-IV patients. In this cohort, three well-described SNPs in the RAGE gene were analyzed. RAGE protein expression was highly upregulated in primary melanomas compared to benign nevi in the two TMA (p < 0.001 and p = 0.005) as well as in sun-exposed melanomas (p = 0.046). sRAGE and esRAGE were identified as prognostic markers for survival as diminished sRAGE (p = 0.034) and esRAGE (p = 0.012) serum levels correlated with poor overall survival (OS). Multivariate Cox regression analysis showed that diminished serum sRAGE was independently associated with poor survival (p = 0.009). Moreover, diminished sRAGE was strongly associated with impaired OS in the second cohort (p < 0.001). Multivariate Cox regression analysis including the investigated SNPs revealed an independent correlation of the two interacting promoter SNPs with impaired OS. In conclusion, the soluble forms of RAGE and variants in its genetic locus are prognostic markers for survival in melanoma patients with high risk for progression. This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi: 10.1002/ijc.29619
INTRODUCTION
Melanoma initiation, growth and progression have been associated with micro-environmental factors which orchestrate tumor-stroma interactions. 1, 2 However, the importance of these factors for predicting disease progression has not yet been established in a clinical setting. In the clinical care of melanoma patients, early detection of disease progression by biomarkers is crucial to guide treatment decisions and to improve outcome, especially in asymptomatic patients with advanced melanoma (stage III or IV following the criteria of the American Joint Committee on Cancer [AJCC]). Several serological biomarkers have been described to determine the prognosis of patients with distant melanoma metastases. 3, 4 Among them, S100B and lactate dehydrogenase (LDH) are most widely used in clinical practice. However, only LDH has been included into the AJCC staging system for patients with stage IV melanoma. Moreover, the standard melanoma biomarker S100B lacks sensitivity to detect melanoma progression in up to 20% of patients with asymptomatic but image-detected metastases. 5 Consequently, there remains a high demand for new, valid markers that predict the risk of disease progression, particularly in the case of loco-regional and distant metastasis with low or even no tumor burden.
Previously, we have demonstrated that the receptor for advanced glycation end-products (RAGE) is a driver of inflammation-associated tumorigenesis by sustaining a chronic inflammatory tumor microenvironment. 6 The RAGE molecule belongs to the immunoglobulin superfamily and represents a membrane-bound pattern-recognition receptor for alarmins. 7, 8 Interaction between RAGE and its ligands amplifies the pro-inflammatory response. 7 A soluble form of RAGE (sRAGE) is known to be generated by shedding via ADAM10 or by alternative splicing 9 and is abundant in plasma/serum of healthy persons, where it is thought to act as decoy for its ligands. 7 Total sRAGE mainly consists of both sRAGE cleaved from full-length RAGE and esRAGE, a splice variant representing only 20-25 % of total sRAGE levels. [9] [10] [11] RAGE-binding alarmins, also known as damage-associated molecular pattern molecules (DAMPs), are released upon damage or cellular stress and are able to activate 6 immune responses similar to cytokines. [12] [13] [14] The melanoma biomarker S100B belongs to this group of danger signaling molecules and is known to interact with RAGE.
12, 15 Recently, three naturally occurring, functional genetic variants within the AGER locus encoding for RAGE have been studied. The single nucleotide polymorphisms (SNPs) -429T/C (rs1800625) and -374T/A (rs1800624) are located in the promoter region and have been shown to increase transcriptional activity of RAGE. [16] [17] [18] Presence of these promoter
SNPs correlates with higher disease activity of various inflammatory diseases such as rheumatoid arthritis or Crohn's disease. 19 Furthermore, the SNP G82S in exon 3 affects glycosylation of the receptor molecule and thereby enhances ligand binding. 16, 20 The G82S polymorphism is associated with higher activity of various diseases such as Alzheimer's disease 21 and correlates with higher risk for diabetic complications. 22 To date, the functional role of these well-described SNPs within the genetic locus of RAGE have not been studied in melanoma patients.
The aim of this study was to investigate soluble forms of RAGE as putative biomarkers for human malignant melanoma. Therefore, measurements of sRAGE in two independent cohorts of patients were conducted and the impact of sRAGE on survival was assessed.
Moreover, the genotypes of the three functional RAGE polymorphisms -429T/C, -374T/A, and G82S were determined and their prognostic impact for high-risk melanoma patients was evaluated.
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MATERIALS AND METHODS

Patients
For this study, two independent sets of plasma and serum samples from 402 melanoma patients (stages I-IV) were analyzed ( Samples were selected according to the following criteria: histologically confirmed melanoma, complete documentation of medical history, primary tumor characteristics, course of the disease, and follow-up. The collection of plasma or serum and documentation of clinical data were performed after patients' informed consent with institutional review board approval. Disease staging was done according to the criteria of the AJCC. 23 Detailed patient characteristics are presented in Table 2 . Blood draw was done using gel-coated serum tubes or EDTA-coated plasma tubes (Sarstedt). After centrifugation, serum and plasma was stored at -20 or -80 °C, respectively.
Determination of circulating levels of sRAGE and esRAGE
Concentration of circulating levels of RAGE (sRAGE) and of the endogenous secretory splice variant esRAGE were measured in duplicate using sandwich ELISA kits (R&D Systems, Minneapolis, MN and B-Bridge International, Tokyo, Japan). S100B serum levels had been determined routinely during regular follow-up with Elecsys S100 immunoassay (Roche Diagnostics AG, Rotkreuz, Switzerland, ULN = 0.1 ng/mL) according to the instructions of the manufacturer, and LDH was determined by conventional central laboratory analysis with an ULN = 250 U/L.
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Receptor-Ligand interaction in vitro
Freshly collected blood from healthy donors was centrifuged at 3,000 U/min for 15 min.
Serum was harvested and incubated with bovine S100B (Merck Chemicals Ltd., Nottingham, UK) at different final concentrations ranging from 0 mg/L to 100 mg/L at 37°C for 24h. After incubation, sRAGE levels were determined via ELISA (R&D Systems, Minneapolis, MN)
according to the manufacturer's instructions.
Tissue Microarray (TMA)
Two independent TMAs were conducted using formalin fixed and paraffin embedded tissue according to a previous report (Table 1) . 24 Briefly, tissue punch samples (0.6 mm diameter)
were taken from tumor or nevus tissue, respectively, and collected in a single TMA block Immunohistochemical staining was performed as described previously. 6 Briefly, after deparaffinization and antigen retrieval, the slides were washed and incubated with blocking serum (0.1% bovine serum albumin in PBS plus 5% normal rabbit serum) for 1 hour followed by avidin-biotin blocking reagent. 
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Soluble RAGE and RAGE polymorphisms in melanoma 9 analyzed based on pathological scoring as previously described. 25 In our study, the intensity 0 and 1 were combined and named "low intensity" and intensity 2 and 3 were combined and named "high intensity" (Supporting Information Figure S6 ). In case of discordant scoring results a consensus score was assigned. TMA spots with a lack of tumor tissue or crush artifacts were excluded from the analysis. Tissue samples were divided into sun-exposed vs.
non sun-exposed based on the evaluation of severe collagen degeneration within the tissue punch or in the whole tissue specimen. Statistical significance was calculated by two-sided
Fisher's exact test as it is recommended for sample sizes less than 1000.
Selection of polymorphisms and genotyping
The three single nucleotide polymorphisms (SNPs) -374T/A (rs1800624), -429T/C (rs1800625), and G82S (rs2070600) in the RAGE gene (AGER gene locus) were investigated because of either enhancing transcriptional activity (-374T/A and -429T/C) or showing enhanced ligand binding (G82S). 16, 17 Human genomic DNA was obtained from the centrifuged blood cells of the EDTA blood samples from cohort 2 by using a kit from Qiagen (Valencia, CA, USA) according to manufacturer's instructions. Genotyping of the SNPs was done by using a PCR-based approach (RFLP) that had already been described and validated. 26 Briefly, for amplification of the region containing the two promoter SNPs (-374T/A and -429T/C), the following primers were used: forward primer 5'-GGGGCAGTTCTCTCCTCACT-3' and reverse primer 5'-GGTTCAGGCCAGACTGTTGT-3'.
For amplification of the region in exon 3 containing the G82S SNP, 5'-GTAAGCGGGGCTCCTGTTGCA-3' was used as forward primer, and 5'-GGCCAAGGCTGGGGTTGAAGG-3' as reverse primer. For enzyme digestion of the resulting PCR products, the enzymes MfeI (for -374T/A) and AluI (for -429T/C and G82S)
were utilized.
Statistics
Cut-off values for marker proteins were calculated utilizing a previously described algorithm of maximally selected statistics that accounts for multiple testing and thereby prevents from a large alpha error. 27 Based on data from the manufacturer of the RAGE ELISA that indicated 
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Soluble RAGE and RAGE polymorphisms in melanoma 10 higher sRAGE levels in serum as compared to plasma, separate cut-off values for serum and plasma sRAGE were calculated. Cut-off values for sRAGE used in this study were 1012.07 pg/mL (serum) and 316.6 pg/mL (plasma). For serum esRAGE, a cut-off value of 321 pg/mL was calculated.
Estimates of cumulative overall survival probabilities according to Kaplan-Meier were compared using two-sided log-rank test statistics. Multivariate Cox proportional hazard analyses were used to evaluate the independent effects of sRAGE and the polymorphisms on OS. The models were stratified by stage to account for stage-dependent differences, and adjustment was made for age and sex of the patients. Results of the Cox models were described by means of hazard ratios (HRs) together with 95% confidence intervals (CIs), and P values were calculated based on the Wald test. Associations between serum markers were calculated by two-sided Spearman's rank correlation coefficient method. Receiver operating curve analyses were calculated using the R package 'pROC'. 28 Relative sRAGE concentrations were compared using two-sided Student's t-test.
Throughout the analyses, P values less than 0.05 were considered statistically significant. All analyses were carried out using R version 3.0.1 (The R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
RAGE protein is abundantly expressed in malignant melanoma
Melanoma tissue-microarray analysis representing 35 primary melanomas and 41 associated benign nevi by immunohistochemistry using a specific antibody against RAGE revealed abundant expression of RAGE in melanoma and stromal cells but less expression in tissue of benign nevi (p < 0.001; Table 1 and Figure 1 A, B) . Tissue samples from sun-exposed areas presenting signs of UV damage were associated with higher RAGE expression ( 
Serum levels of soluble RAGE predict overall survival in stage III/IV melanoma patients
Previously, diminished levels of soluble forms of RAGE were identified in patients with chronic inflammatory diseases such as rheumatoid arthritis. 29 Moreover, sRAGE is thought to act as a decoy for its ligands and thereby to inhibit RAGE signaling. Based on these findings, we hypothesized that sRAGE levels diminish when the soluble receptor engages with one of its ligands e.g. with S100B which is abundantly expressed and released by melanoma cells.
Therefore, serum of healthy donors was incubated with full-length bovine S100B protein with increasing concentrations and sRAGE levels were measured 24 hours after. Soluble RAGE levels diminished significantly in a S100B concentration-dependent manner (Supporting Information Figure S1 ). Therefore, we assumed that sRAGE might also be diminished in melanoma patients, especially in patients with elevated S100B levels, and thereby might bea potentially useful biomarker for disease progression. Subsequently, we measured soluble forms of RAGE (sRAGE and esRAGE) in the serum of an identification cohort (cohort 1)
representing 229 stage III-IV melanoma patients ( Table 2 ). As expected, by conducting a 
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Soluble RAGE and RAGE polymorphisms in melanoma 12 small meta-analysis, we found that mean serum sRAGE was lower in the melanoma patients of cohort 1 compared to healthy individuals (Supporting Information Figure S2 A).
Importantly, diminished serum sRAGE levels were identified as being significantly associated with impaired survival (p = 0.034; Figure 2 A). The endogenous splice variant esRAGE showed similar prognostic impact as sRAGE in cohort 1 (Figure 2 B) . Moreover, sRAGE and esRAGE correlated significantly as well as ∆sRAGE (i.e. cleaved sRAGE only, representing the calculated difference between sRAGE and esRAGE) and esRAGE (Supporting Information Figure S3 ). Therefore, esRAGE measurement was not considered further in cohort 2. Receiver operating characteristic (ROC) analysis showed that the combination of S100B and sRAGE was able to predict OS better than S100B alone or S100B in combination with LDH (Figure 2 C) . Moreover, multivariate Cox regression analysis including sRAGE and the established biomarkers S100B and LDH as well as stage and sex identified diminished sRAGE as an independent prognostic marker for impaired overall survival in two models with S100B and LDH, or LDH alone (Table 3) . In the first model, LDH did not add independent prognostic information, which was probably due to its strong correlation with S100B (Spearman's rho = 0.46, p < 0.001, data not shown). Therefore, we performed Cox proportional hazards analysis without consideration of S100B (Table 2 , model 2). In this second model, LDH and sRAGE correlated both independently with OS.
Diminished sRAGE is confirmed as a prognostic marker in melanoma patients
In an approach to validate the prognostic impact of sRAGE in the peripheral blood, we measured plasma levels of sRAGE in an independent second cohort ( Table 2) . Here, 173 stage I-IV melanoma patients were included for analysis. Median follow-up was 13.8 months.
Again, mean plasma sRAGE was lower in these patients compared to healthy individuals (Supporting Information Figure S2 B ). Diminished sRAGE levels were once more associated with impaired survival (p < 0.001). In cohort 2, patients with diminished plasma sRAGE levels had an unfavorable outcome with a 1-year survival rate of 46.9% whereas patients with normal plasma sRAGE levels did significantly better with a 1-year survival rate of 86.9% (p < 0.001) (Figure 3 A) . Interestingly, plasma sRAGE levels stratified subgroups of stage IV 
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Soluble RAGE and RAGE polymorphisms in melanoma 13 patients. M1c patients with diminished sRAGE levels showed drastically reduced overall survival (1-year survival rate 33.3%) compared to M1c patients with normal sRAGE levels (1-year survival rate 63.3%, log-rank p = 0.0052) (Figure 3 B) . In contrast, the latter group of patients exhibited a comparable 1-year survival rate as M1a/b patients (63.3% vs. 59.2%, log-rank p = 0.94).
Genetic variants of RAGE may predict survival of melanoma patients
Genetic variants of RAGE have been associated with functional activity of the RAGE signaling pathway. In order to investigate for their association with survival of melanoma patients, we performed genotyping of three well-described functional SNPs in the RAGE gene (G82S, -374T/A, and -429T/C, Supporting Information Figure S4 ) using a PCR-based approach termed restriction fragment length polymorphism (RFLP) using genomic DNA obtained from peripheral blood cells of all EDTA blood samples from cohort 2. In our data set, no correlation between SNP status and sRAGE plasma levels was observed (G82S: p = 0.37, -374T/A: p = 0.87, -429T/C: p = 0.98) (Supporting Information Figure S5 ). Additionally, none single SNP was associated with OS (Supporting Information Table S1 ). However, multivariate Cox regression analysis revealed the presence of both promoter SNPs as an independent prognostic marker for impaired OS (p = 0.040, Supporting Information Table   S1 ).
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DISCUSSION
RAGE represents a central driver of tumorigenesis by sustaining an inflammatory tumor microenvironment. 6 Moreover, damage-associated molecular pattern molecules (DAMPs) and its receptors such as RAGE have gained further interest recently as the role of tumorpromoting inflammation has been identified as an attractive target of innovative anti-tumor therapies. 30, 31 This study explores the importance of the DAMP receptor RAGE as a clinically useful prognostic biomarker of disease progression in melanoma patients.
Using two independent tissue-microarrays, our study revealed abundant expression of RAGE protein in malignant melanoma compared to benign nevi. RAGE expression has been detected in various types of cancer, e.g. colorectal, pancreatic and squamous cell carcinoma and its expression has been correlated with more aggressive types of cancer. 14, [32] [33] [34] [35] [36] This supports previous findings of RAGE expression in various melanoma cell lines. 37, 38 Moreover, genetic evidence in various mouse models has revealed RAGE as a central receptor that promotes inflammation-associated tumorigenesis.
6,39-41
In our study, RAGE protein expression was abundant in melanoma tissue compared to benign nevi underlining the importance of RAGE in melanomagenesis. Additionally, its high expression in melanomas with chronic UV damage sheds light on a possible role of RAGE signaling in the process of UV-associated melanoma development. 31 In order to translate these findings to the clinical challenge of early detection of progressing melanoma patients, we evaluated the presence of circulating soluble forms of RAGE in serum/plasma of melanoma patients and its ability to predict overall survival. Using two independent patient cohorts, we demonstrated that diminished levels of a circulating soluble form of RAGE (sRAGE) in the peripheral blood of melanoma patients independently predict overall survival.
LDH and S100B are the most commonly used melanoma markers in clinical routine, and both have been shown to be reliable markers for survival of patients with distant metastasis (AJCC stage IV). Nevertheless, there is still a need for new biomarkers as the standard melanoma biomarker S100B fails to detect melanoma progression in up to 20% of patients. 
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By including sRAGE, S100B, and LDH in a multivariate Cox proportional hazards model, we demonstrated that serum sRAGE independently provides additional prognostic information compared to the established biomarkers. Although sRAGE has not been studied in melanoma patients so far, diminished serum sRAGE levels have been observed in other forms of cancer (e.g. breast cancer 26 , lung cancer 42 , and pancreatic cancer 43 ). Diminished levels of esRAGE were associated with a higher risk for developing pancreatic cancer within the first two years of follow-up. 44 In addition to these data, elevated levels of the RAGE ligands S100A8/A9 and HMGB1 have already been described in sera of cancer patients (e.g.
colorectal, prostate, breast or oral squamous cell cancer). 45 RAGE expression is ubiquitous and can be detected not only in melanoma cells but also in various immune cells and in endothelial cells. 7, 8 sRAGE is released from these cells to the extracellular space and thought to consist of distinct variants of the receptor for advanced glycation end-products: predominantly (1) cleaved forms of membrane-bound full-length RAGE shed by metalloproteinases like ADAM10 and MMP9 -both abundant in the tumor microenvironment, (2) the endogenous splice variant esRAGE representing approximately 20-25% of total sRAGE levels, and (3) other splice variant forms of RAGE. 8, 9, 1010, 47 Moreover, previous studies were not able to detect full-length RAGE in the peripheral blood suggesting cellular damage or necrosis an unlikely way of release. 10 Otherwise, the quest for the celltype specific source of sRAGE needs to be addressed by further studies. To evaluate whether the prognostic potential of total sRAGE is due to the cleaved form or the endogenous splice variant, we measured esRAGE in the serum samples of cohort 1. In our study, sRAGE and esRAGE levels seemed to be coordinately released to the peripheral blood as both markers correlated strongly. Additionally, a similar correlation is seen with esRAGE and cleaved sRAGE (= ∆sRAGE), i.e. sRAGE minus esRAGE (Supporting Information Figure S3 ). This supports recent studies demonstrating a strong similarity between total sRAGE and esRAGE levels.
11
The correlation between diminished levels of sRAGE and impaired survival supports the hypothesis, that sRAGE serves as a decoy for RAGE activating ligands thereby blocking 
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Soluble RAGE and RAGE polymorphisms in melanoma 16 cellular RAGE-RAGE ligand engagement and subsequently preventing cellular RAGEmediated membrane-bound RAGE and thereby inhibits RAGE down-stream signaling. 7, 15, 46 sRAGE therefore could act as an intrinsic inhibitor of RAGE. Moreover, the S100B concentration-dependent decrease of sRAGE in vitro could at least partly explain diminished sRAGE levels in cancer patients and melanoma patients with impaired survival. It seems likely that RAGE-specific ELISA capture and detection antibodies are not able to bind RAGE molecules anymore when their binding sites are occupied by ligands. However, the S100B concentration at which sRAGE diminished in vitro was much higher than S100B concentrations one would expect in patients' sera. This is explained by the fact that RAGE ligands other than S100B are additionally upregulated in the serum of melanoma patients.
Moreover, S100B concentrations could be much higher at the tumor site and in its microenvironment than in the peripheral blood. However, additional studies are required to clarify whether diminished sRAGE levels in melanoma patients with poor prognosis solely result from increasing levels of RAGE ligands such as S100B, S100A8/A9, or HMGB1, or whether they result from diminished release or enhanced down-regulation in melanoma or stromal cells to the benefit of enhanced expression of full-length RAGE. The latter hypothesis is supported by the notion that sRAGE levels add significant prognostic impact to the multivariate model independently of S100B, and that sRAGE serum levels did not correlate with S100B (Spearman's rho = -0.09, p = 0.17). However, the positive predictive value (PPV) of sRAGE alone was relatively low (Cohort 1: PPV = 0.380, Cohort 2: PPV = 0.474) possibly due to a relatively high number of high risk patients in cohort 1 (n = 100 for patients with low serum sRAGE compared to n = 129 for patients with high serum sRAGE) or a shorter followup period in cohort 2 leading to a biased PPV calculation. Despite these data, the combination of S100B and sRAGE was a better predictor of overall survival than S100B
alone or S100B in combination with LDH (sRAGE and S100B: PPV = 0.826, S100B alone: 
nucleotide polymorphisms) of relevant genes have been implicated in melanoma pathogenesis. 48 Naturally-occurring, functional genetic variants within the AGER locus encoding for RAGE have been described recently. The SNPs -429T/C (rs1800625) and -374T/A (rs1800624) are situated in the AGER promoter region and have been shown to increase transcriptional activity of RAGE. [16] [17] [18] However, the functional role of these welldescribed SNPs within the genetic locus of RAGE has not been studied in melanoma patients so far. The variants of the two promoter SNPs (-374T/A, and -429T/C) showed a significant interaction and were associated with significantly impaired survival in a multivariate analysis, but not in univariate analysis (data not shown). Several reports have linked genetic variants of RAGE with an impaired prognosis of various cancer types e.g.
gastric or lung cancer. 49, 50 Moreover, the aforementioned findings highlight the importance of RAGE transcriptional activity in cancer and inflammation, since an association to these promoter SNPs is detected with higher disease activity of various inflammatory diseases such as rheumatoid arthritis or Crohn's disease. 19 Further evaluation of SNPs in the AGER locus using larger patient cohorts and extended genomic analyses will be required to clarify the role of genetic variants of RAGE in malignant melanoma.
Besides its role as prognostic marker in melanoma patients, RAGE signaling may serve as an attractive therapeutic target in melanoma. Possible strategies for inhibiting RAGE signaling using recombinant sRAGE, inhibitory antibodies against RAGE or its ligands, or small-molecule inhibitors have already demonstrated inhibitory effects on tumor growth in various mouse models. 34, 37, 46, 51, 52 Despite its retrospective nature and restricted sample size, that limits subgroup analyzes, this study is the first to establish sRAGE as an independent prognostic blood-based marker for survival in melanoma patients with a high risk for progression. Together with the abundant expression of RAGE in malignant melanoma compared to benign nevi, this study supports the hypothesis that RAGE signaling might play an important role in melanoma. Further studies are required to validate these findings and to further investigate the implications of variants with its genetic locus on RAGE expression and prognosis of melanoma patients. In
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This article is protected by copyright. All rights reserved. Table 1 . Detailed description of the two independent tissue-microarrays. Table 2 . Patient characteristics at the time point of blood withdrawal for serum analysis. Table 3 . Multivariate Cox regression models for overall survival in cohort 1.
Supporting Information Figure S1 . Representative microphotographs of a two independent tissue-microarrays containing primary melanomas and benign nevi analyzed by immunohistochemistry using a specific antibody against RAGE. Scale bars 100µm (lower magnification), 50µm (higher magnification). (B) Staining intensity of RAGE in 35 primary melanomas and 41 associated benign nevi of TMA 1, and (C) in 257 primary melanomas and 22 benign nevi of TMA 2 based on pathological scoring. (D) Staining intensity of RAGE in sun-exposed vs. non sun-exposed melanomas of TMA 1. Severe collagen degeneration was interpreted as sign of sun exposure. Statistical significance between patient numbers with low or high staining intensity was calculated by twosided Fisher's exact test (*p < 0.05; **p < 0.01; ***p < 0.001). 595x793mm (96 x 96 DPI) Figure 2 . Kaplan-Meier estimates of overall survival of the 229 stage III/IV melanoma patients from cohort 1 according to serum concentration of (A) sRAGE and (B) esRAGE. Cut-off values were 1012.07 ng/L for sRAGE and 321 ng/L for esRAGE. Statistical differences were calculated by two-sided log-rank test. (C) The predictive ability of the combination of S100B and sRAGE compared with S100B and LDH, and single markers by receiver operating characteristic (ROC) curves. The resulting AUC (area under the curve) values
show that the combination of S100B and sRAGE was the best predictor of overall survival. 114x152mm (300 x 300 DPI) Figure 3 . (A) Kaplan-Meier estimates of overall survival of the 173 stage I-IV melanoma patients from cohort 2 according to plasma concentration of sRAGE with a cut-off value of 316.6 ng/L. P value was calculated by two-sided log-rank test. (B) Kaplan-Meier estimates of overall survival of the 64 stage IV melanoma patients from cohort 2 according to M stage and plasma concentration of sRAGE. P value was calculated by two-sided log-rank test considering all stage IV patients. 114x152mm (300 x 300 DPI)
